What is amphetamine used for?

Indications and Usage, quoted from the label by Aurolife Pharma, LLC (ANDA211639). Cross-references to other label sections are left out.

Amphetamine Sulfate Tablets USP are indicated for:

• Narcolepsy
• Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted.
• Exogenous Obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patient’s refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines (see CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in use of the drug, such as those described below.

Source: DailyMed label, set id 20735c2e-6304-425f-a4e4-584f6f90d6a0, version 10, effective August 20, 2026. NDC 13107-259, one of 35 listings for this product.

Indications and Usage, quoted from the label by Teva Pharmaceuticals, Inc. (ANDA209253). Cross-references to other label sections are left out.

Amphetamine extended-release orally disintegrating tablets are a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Limitations of Use The use of amphetamine extended-release orally disintegrating tablets are not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Source: DailyMed label, set id 243e88e7-6621-47e9-8d5c-3f79bcb088bb, version 3, effective September 1, 2025. NDC 0480-3315, one of 6 listings for this product.